Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Inhaled aminoglycoside antibiotic

TOBI (tobramycin (inhaled))

Also marketed as TOBI Podhaler and Bethkis and Kitabis Pak. An approved treatment for Cystic Fibrosis.

FDA Approved (1997)by Viatris Specialty LLC (TOBI and TOBI Podhaler); Chiesi USA (Bethkis); PARI Respiratory Equipment (Kitabis Pak); generic solutions from several makers
Preclinical
Phase 1
Phase 2
Phase 3
Approved
1997

Drug facts

The same compound appears under different names depending on the context. Here is how to identify Tobramycin (inhaled) wherever you encounter it, plus the key facts at a glance.

Generic name
Tobramycin (inhaled)
Brand names
TOBI, TOBI Podhaler, Bethkis, Kitabis Pak
Drug class
Inhaled aminoglycoside antibiotic
Manufacturer
Viatris Specialty LLC (TOBI and TOBI Podhaler); Chiesi USA (Bethkis); PARI Respiratory Equipment (Kitabis Pak); generic solutions from several makers
How it's taken
Inhaled twice a day in 28-day courses, through a nebulizer or the Podhaler inhaler

An antibiotic breathed into the lungs twice a day, in 28-day courses with 28 days off between them, for people with cystic fibrosis whose airways carry the germ Pseudomonas aeruginosa[1].

  • Inhaled tobramycin comes as several separate products: TOBI, a liquid for a nebulizer first approved on December 22, 1997; TOBI Podhaler, a dry powder in capsules for a small handheld inhaler approved on March 22, 2013; Bethkis, a smaller-volume liquid approved on October 12, 2012; and Kitabis Pak, tobramycin liquid packed with its own nebulizer, approved on December 2, 2014[5][6][7][8].
  • Generic tobramycin inhalation solutions from several makers are also sold[10]. None of the 4 labels has a boxed warning, and each warns about breathing tightness, hearing damage, kidney damage, muscle weakness and harm to an unborn baby[1][2][3][4].
Follow TOBI by email

We'll email you when TOBI's FDA label changes, when the FDA acts on it, and when new trials for Cystic Fibrosis open. Unsubscribe anytime.

You'll get, for Cystic Fibrosis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.

We never share your email. Unsubscribe anytime. Privacy policy · Check any health site

Where Tobramycin (inhaled) fits

Inhaled tobramycin, sold as TOBI, TOBI Podhaler, Bethkis, Kitabis Pak and generic solutions, is an antibiotic approved since 1997 for people with cystic fibrosis whose lungs carry Pseudomonas aeruginosa, taken twice a day in 28-day courses with 28 days off between them[1][5].

  • Inhaled tobramycin fights the infection and does not change the faulty CFTR protein, which is what the CFTR modulators approved for cystic fibrosis, such as Trikafta for ages 2 and older and Alyftrek for ages 6 and older, are designed to do for people with a responsive CFTR variant[17][18].
  • Pulmozyme (dornase alfa), an inhaled enzyme that thins airway mucus, is approved for use alongside standard therapies, and about 77% of people in the TOBI trials were also using dornase alfa[16][1].
  • Cayston (aztreonam) is the other inhaled antibiotic approved for cystic fibrosis with Pseudomonas aeruginosa, taken 3 times a day for 28 days through the Altera nebulizer from age 7[15].
  • A Gilead-sponsored, open-label Phase 3 trial (NCT00757237) randomly assigned 273 people 6 and older to 3 courses of Cayston or tobramycin nebulizer solution 300mg twice a day[13][14].
  • After 1 course, FEV1 rose by an average relative 8.35% on Cayston and 0.55% on tobramycin, and the authors reported statistical superiority for Cayston in lung function over the 3 courses, along with fewer respiratory hospitalizations (Assael and colleagues, Journal of Cystic Fibrosis, 2013)[13].
  • Within the Viatris products, an open-label trial of TOBI Podhaler against TOBI solution was designed mainly to test safety, and cough (48% against 31%) and stopping for side effects (14% against 8%) were more common with the powder[2].
  • Anyone with Pseudomonas in their lungs can ask their CF care team which inhaled antibiotic and device suit them, how the 28-day courses fit with their CFTR modulator and Pulmozyme, and whether hearing tests make sense.

How Tobramycin (inhaled) works

In cystic fibrosis, thick mucus lets bacteria settle in the airways, and Pseudomonas aeruginosa is the germ all of these labels are written for[1]. Tobramycin is an aminoglycoside antibiotic that acts mainly by disrupting how bacteria make proteins, which damages the bacterial cell envelope and kills the cell, according to the TOBI label[1].

Tobramycin does not cross body linings easily, so after inhalation most of it stays in the airways[1]. Sputum held an average of 1,237mcg of tobramycin per gram 10 minutes after a first 300mg dose of TOBI, while blood an hour after the dose averaged 0.95mcg/mL, and the drug did not build up in sputum over 20 weeks[1]. Sputum levels fell to about 14% of the 10-minute level within 2 hours[1].

Tobramycin is not broken down by the body; what is absorbed leaves in the urine, and what is not absorbed is probably coughed out in sputum[1]. In the TOBI trials, Pseudomonas counts in sputum fell during the 28 days on the drug and returned to where they started during the 28 days off, and the drop was smaller with each later cycle[1]. Inhaled tobramycin treats the infection and does not change the faulty CFTR protein that causes cystic fibrosis.

Side effects and safety

What patients report
Label warnings
  • No boxed warning. none of the TOBI, TOBI Podhaler, Bethkis or Kitabis Pak labels has a boxed warning
  • Allergy to aminoglycosides. TOBI is not used in anyone with a known allergy to any aminoglycoside antibiotic
  • Bronchospasm. the airways can tighten after an inhaled dose, causing wheezing or shortness of breath, and the doctor treats it as needed
  • Hearing and balance damage (ototoxicity). ringing in the ears (tinnitus) can be an early sign; hearing loss has been reported after approval, and dizziness or spinning can signal balance damage. People who carry certain variants in the mitochondrial MT-RNR1 gene, especially m.1555A>G, or whose mother had aminoglycoside hearing loss, have a higher risk of permanent hearing loss
  • Kidney damage (nephrotoxicity). not seen in the TOBI trials but linked to aminoglycosides as a class; people with kidney problems or on other kidney-harming drugs may need blood tobramycin levels and kidney tests
  • Muscle weakness. aminoglycosides can worsen muscle weakness in people with myasthenia gravis or Parkinson's disease, and breathing paralysis can occur, more often with neuromuscular disorders or with muscle-relaxing drugs used in surgery
  • Pregnancy. aminoglycosides can harm an unborn baby; streptomycin, a related drug, has caused permanent deafness in babies exposed in the womb, though little inhaled tobramycin reaches the blood
  • IV or injected aminoglycosides at the same time. people also getting tobramycin or a related antibiotic by vein are monitored, including blood tobramycin levels
Most common in trials
TOBI against placebo: voice changes (13% against 7%) and ringing in the ears (3% against 0%) were the only side effects reported significantly more oftenTOBI against placebo: cough (46% against 47%), sore throat (38% against 39%), more sputum (38% against 40%), shortness of breath (34% against 39%), coughing up blood (19% against 24%), taste changes (7% against 7%) and rash (5% against 6%)TOBI Podhaler against TOBI solution: cough (48% against 31%), voice changes (14% against 4%), sore throat (14% against 11%), shortness of breath (16% against 12%) and fever (16% against 12%)Bethkis: lower FEV1 readings, crackling lung sounds, a raised blood inflammation test (sedimentation rate) and voice changes were more common than on placebo
What gets monitored
  • Hearing tests (audiograms) and blood tobramycin levels for people with known or suspected hearing or balance problems
  • Blood tobramycin levels and kidney function tests for people with kidney problems or taking other kidney-harming drugs
  • Kidney function in older adults, since tobramycin leaves the body through the kidneys
  • Ampules not used if cloudy, if particles show, or after more than 28 days at room temperature
Report a suspected reaction to Viatris at 1-877-446-3679 for TOBI or TOBI Podhaler, Chiesi USA at 1-888-661-9260 for Bethkis, PARI at 1-844-548-2247 for Kitabis Pak, or FDA MedWatch at 1-800-FDA-1088, or to the FDA at 1-800-FDA-1088.
In context

None of the inhaled tobramycin labels has a boxed warning[1][2][3][4]. TOBI is not used in anyone with a known allergy to any aminoglycoside antibiotic[1]. The TOBI label warns that the airways can tighten after a dose (bronchospasm), that ringing in the ears and hearing loss have been reported, that aminoglycosides as a class can damage the kidneys, that they can worsen muscle weakness in people with myasthenia gravis or Parkinson's disease, and that they can harm an unborn baby[1].

In 2 placebo-controlled 24-week trials in 520 people, 258 of them on TOBI and aged 6 to 48, voice changes (13% against 7%) and ringing in the ears (3% against none) were the only side effects reported significantly more often on TOBI[1]. Every episode of ringing in the ears passed without stopping TOBI and came with no hearing loss on hearing tests, though hearing loss has been reported since approval, some of it in people who also had aminoglycosides by vein[1].

Cough, sore throat, more sputum, shortness of breath and coughing up blood were about as common on placebo as on TOBI[1]. Kidney damage was not seen in the TOBI trials, and 3% in each group had a rise in creatinine, a kidney blood test, of at least 50%[1]. The label adds a warning, updated in February 2023, that people with certain variants in the mitochondrial gene MT-RNR1, especially m.1555A>G, have had aminoglycoside hearing damage even with normal blood levels; these variants are found in under 1% of the US population[1].

In the open-label trial comparing the 2 Viatris products in 517 people, cough was reported by 48% on TOBI Podhaler against 31% on TOBI solution, voice changes by 14% against 4%, and 14% against 8% stopped because of side effects[2]. The Bethkis label lists lower FEV1 readings, crackling lung sounds, a raised sedimentation rate and voice changes as more common than on placebo[3].

The TOBI label says to avoid using it with other drugs that can harm the nerves, kidneys or hearing, and not to give it with the water pills ethacrynic acid or furosemide, with urea or with mannitol by vein[1].

This is not a complete list of side effects. Talk to your doctor or pharmacist about what to expect and when to seek medical attention.

Taking Tobramycin (inhaled)

TOBI, Bethkis, Kitabis Pak and the generic solutions are breathed in through a nebulizer, and TOBI Podhaler is a dry powder breathed in through its own handheld inhaler[1][2]. Every product is taken twice a day for 28 days, then stopped for 28 days, then started again, with doses as close to 12 hours apart as possible and never less than 6 hours apart[1][2][3].

The dose is the same at every age and weight[1]. TOBI is 1 ampule of 300mg in 5mL, breathed in over about 15 minutes through a PARI LC PLUS reusable nebulizer with a DeVilbiss Pulmo-Aide compressor[1]. Kitabis Pak contains the same 300mg in 5mL ampules packed with a PARI LC PLUS nebulizer, used with a DeVilbiss Pulmo-Aide compressor[4]. Bethkis is 1 ampule of 300mg in 4mL, given through a PARI LC PLUS nebulizer with a PARI Vios compressor[3].

TOBI Podhaler is 4 capsules of 28mg each, breathed in one at a time through the Podhaler device, twice a day; the capsules are never swallowed, each is taken out of its blister only right before use, and a new device comes in each weekly pack[2]. In its trial, a TOBI Podhaler dose took about 2 to 7 minutes[2]. Nebulized tobramycin is not diluted or mixed with dornase alfa or any other drug in the nebulizer[1].

The TOBI label says people on several treatments take them before TOBI or as their doctor directs, and the TOBI Podhaler label recommends taking TOBI Podhaler last[1][2]. TOBI and Bethkis ampules are kept in the refrigerator and can be kept at room temperature, up to 77°F, for up to 28 days; TOBI Podhaler capsules are kept at room temperature and away from moisture[1][3][2]. A missed dose can be taken up to 6 hours before the next one; with less than 6 hours left, the missed dose is skipped[1].

Availability and cost

Generic available

Generic versions may be available at a lower cost. Ask your pharmacist.

Why it costs what it costs

Generic tobramycin inhalation solution has been FDA approved since October 2013, and the openFDA NDC directory lists generic solutions from more than 10 labelers, including Teva, Lupin, Amneal, Sun, Dr. Reddy's and Ritedose, plus authorized generics of Bethkis and Kitabis Pak[9][10]. TOBI Podhaler has no generic version in Drugs@FDA[6]. None of the labels gives a price. Viatris's savings card covers TOBI Podhaler for commercially insured people, and the Viatris Patient Assistance Program lists both TOBI and TOBI Podhaler for people without prescription coverage[19][20].

Help paying for TOBI

With private insurance, the drugmaker's copay card can lower what you pay for TOBI. Drugmaker copay cards can't be used with Medicare, Medicaid or TRICARE, but charity funds often can. None of the 4 charity funds for Cystic Fibrosis were open on November 16, 2026. Without insurance, you can apply to the drugmaker's free medicine program, which sets its own eligibility rules. Pick your insurance below to see which offers fit you.

Your insurance
From the drugmaker
TOBI (Tobramycin (inhaled))
Some details not published
Viatris Patient Assistance Program and TOBI Podhaler Savings Card
  • Copay help

    TOBI Podhaler Savings Card: patients with commercial insurance that covers TOBI Podhaler pay as little as $0 for each 28-day fill, up to an aggregate maximum of $14,000 per calendar year. Not valid with Medicare (Part D or otherwise), Medicaid, Medigap, VA or DOD, TRICARE or any state or federally funded program, and not valid for uninsured patients. Patient or guardian must be 18 or older and live in the US or its territories. Savings Card line 1-877-999-8624, Monday to Friday, 8 AM to 5 PM ET. Covers TOBI Podhaler only; the page does not mention TOBI solution.

    For: private insurance · source
  • Free medicine program

    Viatris Patient Assistance Program (Group Two): the application lists TOBI 300mg/5mL ampules (56s) and TOBI Podhaler 28mg capsules (224). Applicants must meet the program's financial requirements, be current US residents including territories, be fully uninsured or insured with no prescription drug coverage, and have a prescription from a licensed US prescriber for an FDA-approved use. Enrollment lasts 12 months with up to 11 refills. Phone 888-417-5782, fax 866-792-7945, Monday to Friday, 8 AM to 5 PM Central.

    For: no insurance · source

Good to know: Read on Viatris's TOBI Podhaler savings card page and the Viatris PAP page and its linked Group Two application on November 21, 2026; tobipodhaler.com redirects to the savings card page. The application states no income threshold. No Viatris copay card for TOBI solution was found. Bethkis (Chiesi), Kitabis Pak (PARI) and the generic solutions are not covered by these programs, and their support programs were not checked.

Checked on the drugmaker's official pages on November 21, 2026. Programs change; confirm with the program before you rely on it.

Charity funds for Cystic Fibrosis

  • From a charity · The Assistance Fund
    Cystic Fibrosis fund
    Waitlist

    Pays for: Copays, coinsurance, deductibles and other health-related expenses.

Status as each foundation showed it on November 16, 2026.

Every program and charity fund for Cystic Fibrosis →

More ways to get help paying for treatment →

Insurance said no? Your Insurer Denied a Rare Disease Drug and Fewer Than 1 in 100 People Appeal, So Here Is the Playbook · 14 min read

Clinical trial results

TOBI was approved on 2 identical 24-week trials at 69 US cystic fibrosis centers in 520 people 6 and older with Pseudomonas aeruginosa and FEV1, the air blown out in 1 second, of 25-75% of the expected value[1]. Patients took TOBI 300mg or placebo twice a day in 3 cycles of 28 days on and 28 days off, on top of their usual care, and about 77% were also using dornase alfa[1].

FEV1 rose an average of about 11% from the start in the first trial against no change on placebo, and about 7% in the second against a 1% drop[1]. People on TOBI spent an average of 5.1 days in hospital against 8.1 on placebo, and 40% against 53% needed antibiotics by vein[1]. The combined results were published in the New England Journal of Medicine in January 1999 by Ramsey and colleagues, who reported people on tobramycin were 26% less likely to be hospitalized[12].

The share of patients whose Pseudomonas needed higher tobramycin levels to stop it (16mcg/mL or more) rose from 13% to 23% over 6 months of TOBI[1]. TOBI Podhaler was approved on a placebo-controlled trial in 95 people aged 6 to 21 who had not used an inhaled anti-Pseudomonas antibiotic in the previous 4 months; the trial stopped early for benefit, and FEV1 rose 12.5% on TOBI Podhaler against 0.1% on placebo in the 61 people in the main analysis[2].

A second placebo-controlled Podhaler trial in 62 young people did not reach statistical significance (8.2% against 2.3%)[2]. A third, open-label trial gave 517 mostly adult patients TOBI Podhaler or TOBI solution for 3 cycles; its main purpose was safety, and the label says open-label design and missing data limit what its efficacy results show[2].

Bethkis was approved on 2 placebo-controlled trials in 306 people with FEV1 of 40-80% of expected, plus a bridging study in 324 people for its final formula[3].

Development history

The FDA approved TOBI, tobramycin solution for inhalation, on December 22, 1997 under NDA 050753, and Drugs@FDA now lists Viatris as its holder[5]. Bethkis, a 300mg in 4mL solution from Chiesi, followed on October 12, 2012 under NDA 201820, and TOBI Podhaler, the first dry powder form, on March 22, 2013 under NDA 201688[7][6]. Kitabis Pak, tobramycin solution co-packaged with a PARI LC PLUS nebulizer, was approved on December 2, 2014 under NDA 205433[8].

The first generic tobramycin inhalation solution listed in Drugs@FDA, from Teva, was approved on October 10, 2013, and Drugs@FDA now lists 10 generic applications as marketed prescription products[9][11]. The TOBI label updated in February 2023 reports a new warning about hearing damage in people with mitochondrial MT-RNR1 variants[1]. As of November 21, 2026, Drugs@FDA lists all 4 brands as prescription products still marketed[5][6][7][8].

Ask anything about Tobramycin (inhaled)
AI-powered answers from clinical trial databases, FDA reports, and medical literature
Start withor ask

Explore Cystic Fibrosis trials

Other Cystic Fibrosis treatments

Common questions about Tobramycin (inhaled)

▸What is Tobramycin (inhaled) (TOBI)?

An antibiotic breathed into the lungs twice a day, in 28-day courses with 28 days off between them, for people with cystic fibrosis whose airways carry the germ Pseudomonas aeruginosa[1]. Inhaled tobramycin comes as several separate products: TOBI, a liquid for a nebulizer first approved on December 22, 1997; TOBI Podhaler, a dry powder in capsules for a small handheld inhaler approved on March 22, 2013; Bethkis, a smaller-volume liquid approved on October 12, 2012; and Kitabis Pak, tobramycin liquid packed with its own nebulizer, approved on December 2, 2014[5][6][7][8]. Generic tobramycin inhalation solutions from several makers are also sold[10]. None of the 4 labels has a boxed warning, and each warns about breathing tightness, hearing damage, kidney damage, muscle weakness and harm to an unborn baby[1][2][3][4].

▸How does Tobramycin (inhaled) work?

In cystic fibrosis, thick mucus lets bacteria settle in the airways, and Pseudomonas aeruginosa is the germ all of these labels are written for[1]. Tobramycin is an aminoglycoside antibiotic that acts mainly by disrupting how bacteria make proteins, which damages the bacterial cell envelope and kills the cell, according to the TOBI label[1]. Tobramycin does not cross body linings easily, so after inhalation most of it stays in the airways[1]. Sputum held an average of 1,237mcg of tobramycin per gram 10 minutes after a first 300mg dose of TOBI, while blood an hour after the dose averaged 0.95mcg/mL, and the drug did not build up in sputum over 20 weeks[1]. Sputum levels fell to about 14% of the 10-minute level within 2 hours[1]. Tobramycin is not broken down by the body; what is absorbed leaves in the urine, and what is not absorbed is probably coughed out in sputum[1]. In the TOBI trials, Pseudomonas counts in sputum fell during the 28 days on the drug and returned to where they started during the 28 days off, and the drop was smaller with each later cycle[1]. Inhaled tobramycin treats the infection and does not change the faulty CFTR protein that causes cystic fibrosis.

▸What are the side effects of Tobramycin (inhaled)?

None of the inhaled tobramycin labels has a boxed warning[1][2][3][4]. TOBI is not used in anyone with a known allergy to any aminoglycoside antibiotic[1]. The TOBI label warns that the airways can tighten after a dose (bronchospasm), that ringing in the ears and hearing loss have been reported, that aminoglycosides as a class can damage the kidneys, that they can worsen muscle weakness in people with myasthenia gravis or Parkinson's disease, and that they can harm an unborn baby[1]. In 2 placebo-controlled 24-week trials in 520 people, 258 of them on TOBI and aged 6 to 48, voice changes (13% against 7%) and ringing in the ears (3% against none) were the only side effects reported significantly more often on TOBI[1]. Every episode of ringing in the ears passed without stopping TOBI and came with no hearing loss on hearing tests, though hearing loss has been reported since approval, some of it in people who also had aminoglycosides by vein[1]. Cough, sore throat, more sputum, shortness of breath and coughing up blood were about as common on placebo as on TOBI[1]. Kidney damage was not seen in the TOBI trials, and 3% in each group had a rise in creatinine, a kidney blood test, of at least 50%[1]. The label adds a warning, updated in February 2023, that people with certain variants in the mitochondrial gene MT-RNR1, especially m.1555A>G, have had aminoglycoside hearing damage even with normal blood levels; these variants are found in under 1% of the US population[1]. In the open-label trial comparing the 2 Viatris products in 517 people, cough was reported by 48% on TOBI Podhaler against 31% on TOBI solution, voice changes by 14% against 4%, and 14% against 8% stopped because of side effects[2]. The Bethkis label lists lower FEV1 readings, crackling lung sounds, a raised sedimentation rate and voice changes as more common than on placebo[3]. The TOBI label says to avoid using it with other drugs that can harm the nerves, kidneys or hearing, and not to give it with the water pills ethacrynic acid or furosemide, with urea or with mannitol by vein[1].

▸How is Tobramycin (inhaled) taken?

TOBI, Bethkis, Kitabis Pak and the generic solutions are breathed in through a nebulizer, and TOBI Podhaler is a dry powder breathed in through its own handheld inhaler[1][2]. Every product is taken twice a day for 28 days, then stopped for 28 days, then started again, with doses as close to 12 hours apart as possible and never less than 6 hours apart[1][2][3]. The dose is the same at every age and weight[1]. TOBI is 1 ampule of 300mg in 5mL, breathed in over about 15 minutes through a PARI LC PLUS reusable nebulizer with a DeVilbiss Pulmo-Aide compressor[1]. Kitabis Pak contains the same 300mg in 5mL ampules packed with a PARI LC PLUS nebulizer, used with a DeVilbiss Pulmo-Aide compressor[4]. Bethkis is 1 ampule of 300mg in 4mL, given through a PARI LC PLUS nebulizer with a PARI Vios compressor[3]. TOBI Podhaler is 4 capsules of 28mg each, breathed in one at a time through the Podhaler device, twice a day; the capsules are never swallowed, each is taken out of its blister only right before use, and a new device comes in each weekly pack[2]. In its trial, a TOBI Podhaler dose took about 2 to 7 minutes[2]. Nebulized tobramycin is not diluted or mixed with dornase alfa or any other drug in the nebulizer[1]. The TOBI label says people on several treatments take them before TOBI or as their doctor directs, and the TOBI Podhaler label recommends taking TOBI Podhaler last[1][2]. TOBI and Bethkis ampules are kept in the refrigerator and can be kept at room temperature, up to 77°F, for up to 28 days; TOBI Podhaler capsules are kept at room temperature and away from moisture[1][3][2]. A missed dose can be taken up to 6 hours before the next one; with less than 6 hours left, the missed dose is skipped[1].

▸Is Tobramycin (inhaled) FDA approved?

Yes. The FDA approved TOBI, the first inhaled tobramycin, on December 22, 1997, and TOBI, TOBI Podhaler, Bethkis and Kitabis Pak are each approved for people with cystic fibrosis whose lungs carry Pseudomonas aeruginosa.

Age: none has been shown safe and effective under age 6.

Lung function: the FEV1 range studied was 25-75% of expected for TOBI and Kitabis Pak, 25-80% for TOBI Podhaler and 40-80% for Bethkis.

Not shown: in people colonized with Burkholderia cepacia.

Generic: generic tobramycin inhalation solution has been approved since October 2013; TOBI Podhaler has no generic.

Source: TOBI prescribing information

▸What is the TOBI dose for cystic fibrosis?

TOBI is 1 ampule of 300mg in 5mL breathed in twice a day for 28 days, then 28 days off, repeating the cycle[1].

Timing: doses as close to 12 hours apart as possible, never less than 6 hours apart.

Same for everyone: the dose does not change with age or weight from age 6.

Nebulizer: a PARI LC PLUS reusable nebulizer with a DeVilbiss Pulmo-Aide compressor, over about 15 minutes.

Not mixed: TOBI is not diluted or mixed with dornase alfa or other drugs in the nebulizer.

Source: TOBI prescribing information

▸What is the difference between TOBI, TOBI Podhaler, Bethkis and Kitabis Pak?

All 4 contain tobramycin taken twice a day in 28-day on, 28-day off cycles, but they are separate products with different forms and devices[1][2][3][4].

TOBI: 300mg in 5mL liquid through a PARI LC PLUS nebulizer.

Kitabis Pak: 300mg in 5mL liquid packed together with a PARI LC PLUS nebulizer.

Bethkis: 300mg in 4mL liquid through a PARI LC PLUS nebulizer with a PARI Vios compressor.

TOBI Podhaler: 4 capsules of 28mg dry powder per dose through the handheld Podhaler, taking about 2 to 7 minutes in its trial.

Source: TOBI Podhaler prescribing information

▸Can inhaled tobramycin cause hearing loss?

Hearing loss has been reported in people using TOBI since approval, and ringing in the ears can be an early warning sign[1].

In trials: 3% on TOBI had passing ringing in the ears against none on placebo, with no hearing loss on hearing tests.

Higher risk: people with certain variants in the mitochondrial MT-RNR1 gene, especially m.1555A>G, or a mother with aminoglycoside hearing loss.

Monitoring: people with known or suspected hearing or balance problems may get hearing tests and blood tobramycin levels.

Tell the doctor: about ringing in the ears, dizziness or any change in hearing.

Source: TOBI prescribing information

▸Does TOBI need to be refrigerated?

Yes. TOBI ampules are stored in the refrigerator at 36°F to 46°F[1].

Room temperature: pouches, opened or unopened, can be kept at up to 77°F for up to 28 days.

Color: the slightly yellow liquid may darken out of the fridge, which the label says does not mean a change in quality within those limits.

Do not use: if cloudy, if particles show, or after 28 days at room temperature.

TOBI Podhaler: capsules are kept at room temperature, away from moisture.

Source: TOBI prescribing information

▸Is there a generic for TOBI?

Yes. Generic tobramycin inhalation solution has been FDA approved since October 10, 2013, and many makers sell it[9][10].

Makers: the openFDA NDC directory lists Teva, Lupin, Amneal, Sun, Dr. Reddy's, Ritedose and others, plus authorized generics of Bethkis and Kitabis Pak.

TOBI Podhaler: no generic of the dry powder is listed in Drugs@FDA.

Source: openFDA NDC directory%22&limit=100)

▸Is there help paying for TOBI Podhaler or TOBI?

Viatris offers a savings card for TOBI Podhaler and lists both TOBI and TOBI Podhaler in its free-medicine program[19][20].

Savings card: as little as $0 for each 28-day fill of TOBI Podhaler, up to $14,000 a year, for commercially insured people only; not for Medicare, Medicaid, TRICARE or other government plans.

Free medicine: the Viatris Patient Assistance Program is for US residents who meet its financial rules and are uninsured or have no prescription coverage.

Phone: 1-877-999-8624 for the savings card, Monday to Friday, 8 AM to 5 PM Eastern; 888-417-5782 for the assistance program.

Source: TOBI Podhaler Savings Card

Sources and references

Every factual claim on this page is drawn from the public sources listed below. Click any reference to open the original document.

  1. Viatris Specialty LLC via DailyMed · 2025-11-15. TOBI (tobramycin inhalation solution). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6a3c3871-1d3a-44d6-8be3-526b30123ef7
  2. Viatris Specialty LLC via DailyMed · 2026-04-15. TOBI Podhaler (tobramycin inhalation powder). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c4b5bb1f-e158-4ac1-9c35-e98a416c743a
  3. Chiesi USA, Inc. via DailyMed · 2023-02-24. BETHKIS (tobramycin inhalation solution). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=1cd3d47b-025f-4705-9daf-cf07725ec223
  4. PARI Respiratory Equipment, Inc. via DailyMed · 2024-11-22. Kitabis Pak (tobramycin inhalation solution co-packaged with PARI LC PLUS Reusable Nebulizer). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=da1e5afd-d707-4af1-8935-8195ba6d769f
  5. U.S. Food and Drug Administration · 1997-12-22. TOBI approval history, NDA 050753. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=050753
  6. U.S. Food and Drug Administration · 2013-03-22. TOBI PODHALER approval history, NDA 201688. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201688
  7. U.S. Food and Drug Administration · 2012-10-12. BETHKIS approval history, NDA 201820. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=201820
  8. U.S. Food and Drug Administration · 2014-12-02. KITABIS PAK approval history, NDA 205433. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=205433
  9. U.S. Food and Drug Administration · 2013-10-10. Tobramycin solution for inhalation, Teva, ANDA 091589. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=091589
  10. U.S. Food and Drug Administration (openFDA) · 2026-11-21. NDC directory search for inhaled tobramycin. https://api.fda.gov/drug/ndc.json?search=generic_name:tobramycin+AND+route:%22RESPIRATORY+(INHALATION)%22&limit=100
  11. U.S. Food and Drug Administration (openFDA) · 2026-11-21. Drugs@FDA applications for tobramycin by inhalation. https://api.fda.gov/drug/drugsfda.json?search=products.active_ingredients.name:tobramycin+AND+products.route:INHALATION&limit=100
  12. N Engl J Med 1999;340(1):23-30 (PubMed) · 1999-01-07. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.. https://pubmed.ncbi.nlm.nih.gov/9878641/
  13. J Cyst Fibros 2013;12(2):130-40 (PubMed) · 2013-03. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.. https://pubmed.ncbi.nlm.nih.gov/22985692/
  14. ClinicalTrials.gov. Aztreonam for Inhalation Solution vs Tobramycin Inhalation Solution in Patients With Cystic Fibrosis & Pseudomonas Aeruginosa. https://clinicaltrials.gov/study/NCT00757237
  15. Gilead Sciences, Inc. via DailyMed · 2025-12-01. CAYSTON (aztreonam for inhalation solution). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=67300ca3-8c53-4ce4-8e86-2c03be1f9b8a
  16. Genentech, Inc. via DailyMed · 2025-12-17. PULMOZYME- dornase alfa solution. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d8c78a7e-ff99-48f3-8952-643ec2ea0f86
  17. Vertex Pharmaceuticals Incorporated via DailyMed · 2026-06-22. TRIKAFTA (elexacaftor, tezacaftor and ivacaftor tablets; ivacaftor tablets). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f354423a-85c2-41c3-a9db-0f3aee135d8d
  18. Vertex Pharmaceuticals Incorporated via DailyMed · 2026-08-26. ALYFTREK (vanzacaftor, tezacaftor and deutivacaftor tablets). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7e635909-c6fd-4f0d-ae77-cdff03653a20
  19. Viatris Specialty LLC. TOBI Podhaler | Savings Card. https://cloud.mail.viatrisconnect.com/tobipodhaler-savings-card
  20. Viatris. Viatris Patient Assistance Program (U.S.). https://www.viatris.com/en-us/lm/united-states/patient-assistance-program

This page is for informational purposes only and does not constitute medical advice. Drug information is sourced from public databases and peer-reviewed literature and may not reflect the most recent updates. Always discuss treatment options with your healthcare provider. Last reviewed: November 2026.

Follow TOBI by email

We'll email you when TOBI's FDA label changes, when the FDA acts on it, and when new trials for Cystic Fibrosis open. Unsubscribe anytime.

You'll get, for Cystic Fibrosis:
  • Trial Alerts, when a new trial opens or a trial changes
  • Disease Updates, FDA decisions and condition news, usually 1 or 2 emails a month
Turn either off anytime from the link in every email.
We never share your email. Unsubscribe anytime. Privacy policy · Check any health site